NorthSea Therapeutics: NorthSea Therapeutics B.V.: NorthSea Therapeutics Announces Publication of Positive Results from Phase 2b ICONA Clinical Trial of Icosabutate in Biopsy-Confirmed F1-F3 MASH in Journal of Hepatology
Improvements in fibrosis observed using 3 pre-specified methods of histological analysis: conventional, AIM-MASH (PathAI) and qFibrosis (Histoindex) Mechanistically, icosabutate improved fibrosis ...
Read full article »
NorthSea Therapeutics is a Netherlands-based biotech company that develops novel drugs for the treatment of NASH, inflammatory and metabolic diseases.
Read more